Ana I. Velázquez Mañana, MD, MSc, FASCO· @AnaVManana · X·· 12 小时前评分70
正文 · 原文
On Monday I told a patient with SCLC, this is the treatment plan today, but I’m hoping next week I can bring you better news from #ESMO26
👇 THIS is what we are here for!
🌟 PRACTICE CHANGING update for ES-SCLC: adding tarlatamb to maintenance durvalumab increases median OS by 58% (9mo)
🌟
Congrats to @sands_jacob and to all the DeLLphi-305 investigators!
#ESMO26 #LCSM
102 浏览 · 5 赞 · 4 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Ana I. Velázquez Mañana, MD, MSc, FASCO · x.com